Literature DB >> 9088493

Juvenile obsessive-compulsive disorder.

C Wever1, J M Rey.   

Abstract

OBJECTIVE: To describe the characteristics of a series of children and adolescents with obsessive-compulsive disorder (OCD) and evaluate the outcome of treatment.
METHOD: Type of symptoms, severity before and after treatment and factors associated with outcome were examined in a large group (n = 82) of consecutive OCD cases referred for treatment.
RESULTS: Most children (95%) had both obsessions and compulsions. Symptoms had been present for 2 years on average. Seventy-one per cent (n = 57) of all eligible patients completed a combined behavioural and pharmacological protocol. Among these, there was a 68% remission rate and a 60% decrease of symptoms at 4 weeks. Comorbidity with oppositional defiant disorder and high aggression scores were associated with poor outcome.
CONCLUSIONS: Juvenile OCD can be treated effectively in a standard clinical setting. Treatment programs of the kind described are accepted by young people. It remains to be seen whether in this age group a combined treatment produces better results than medication alone or cognitive-behaviour therapy alone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088493     DOI: 10.3109/00048679709073806

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  9 in total

1.  Family factors predict treatment outcome for pediatric obsessive-compulsive disorder.

Authors:  Tara S Peris; Catherine A Sugar; R Lindsey Bergman; Susanna Chang; Audra Langley; John Piacentini
Journal:  J Consult Clin Psychol       Date:  2012-02-06

2.  Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial.

Authors:  Scott N Compton; Tara S Peris; Daniel Almirall; Boris Birmaher; Joel Sherrill; Phillip C Kendall; John S March; Elizabeth A Gosch; Golda S Ginsburg; Moira A Rynn; John C Piacentini; James T McCracken; Courtney P Keeton; Cynthia M Suveg; Sasha G Aschenbrand; Dara Sakolsky; Satish Iyengar; John T Walkup; Anne Marie Albano
Journal:  J Consult Clin Psychol       Date:  2014-01-13

Review 3.  Family factors in the development and management of anxiety disorders.

Authors:  Ronald M Rapee
Journal:  Clin Child Fam Psychol Rev       Date:  2012-03

Review 4.  Cognitive behavioral treatment for young children with obsessive-compulsive disorder.

Authors:  Jennifer B Freeman; Molly L Choate-Summers; Phoebe S Moore; Abbe M Garcia; Jeffrey J Sapyta; Henrietta L Leonard; Martin E Franklin
Journal:  Biol Psychiatry       Date:  2007-02-01       Impact factor: 13.382

5.  Family involvement in the psychological treatment of obsessive-compulsive disorder: a meta-analysis.

Authors:  Johanna Thompson-Hollands; Aubrey Edson; Martha C Tompson; Jonathan S Comer
Journal:  J Fam Psychol       Date:  2014-05-05

Review 6.  Childhood anxiety disorders and developmental issues in anxiety.

Authors:  Paul Arnold; S Preeya Banerjee; Rashmi Bhandari; Elisa Lorch; Jennifer Ivey; Michelle Rose; David R Rosenberg
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

7.  Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I).

Authors:  Abbe Marrs Garcia; Jeffrey J Sapyta; Phoebe S Moore; Jennifer B Freeman; Martin E Franklin; John S March; Edna B Foa
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-09-06       Impact factor: 8.829

Review 8.  Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents.

Authors:  R T O'Kearney; K J Anstey; C von Sanden
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

9.  The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods.

Authors:  Jennifer B Freeman; Molly L Choate-Summers; Abbe M Garcia; Phoebe S Moore; Jeffrey J Sapyta; Muniya S Khanna; John S March; Edna B Foa; Martin E Franklin
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-01-30       Impact factor: 3.033

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.